{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:58:09Z","timestamp":1790816289703,"version":"4.1.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Cutaneous neurofibromas (cNFs) can cause itching, disfigurement, pain, and emotional difficulties in people with neurofibromatosis type 1 (NF1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the impact of the mitogen-activated protein kinase kinase inhibitor selumetinib on cNF including change in tumor volume and patient-reported outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>Adults with NF1 and 9 or more measurable cNFs were enrolled in this nonrandomized pilot trial at the National Cancer Institute and the University of Alabama at Birmingham, which spanned from August 26, 2017, to August 21, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Participants received selumetinib for up to 24 cycles (1 cycle\u2009=\u200928 days) with restaging visits after every 4 cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Photography and volumetric measurements of cNFs using calipers were used to evaluate the number and volume of tumors. Participants completed the Skindex-29 Quality of Life assessment to quantify the effect of treatment on symptoms, functioning, emotions, itching, and pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 11 participants who enrolled, the median (range) age was 54 (28-75) years, and 6 were female. The median (IQR) best response across all participants and tumors was a \u221228.5% (\u221240.9% to \u221212.5%) decrease in cNF volume from baseline. Some participants showed a visible improvement in cNF burden while receiving treatment in standardized photographs. The median (range) duration of treatment was 9 cycles (1-24), with only 4 participants completing the full 24 cycles of treatment. Two of these participants continued treatment beyond the original 24 cycles due to perceived clinical benefit. All participants experienced at least 1 reversible drug-related adverse event (AE), with cutaneous AEs such as dry skin and rash being the most common. Two participants were removed from treatment due to concern for drug reaction with eosinophilia and systemic symptoms. While the Skindex-29 assessment showed improvement in emotion scores after cycle 1, there were no other significant or durable changes in scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this nonrandomized pilot trial, selumetinib resulted in some decrease in cNF volume; however, there was no sustained improvement in patient-reported outcome measures. Study enrollment was incomplete, in part due to the COVID-19 pandemic, and highlights the challenges of treating patients with cNF with a drug that often leads to dermatologic AEs. Future larger studies using other measurement techniques, such as 3-dimensional photography, could help to yield results that are more generalizable to the phenotypically diverse NF1 population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT02839720\">NCT02839720<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.6574","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T11:32:53Z","timestamp":1740569573000},"page":"533","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib"],"prefix":"10.1001","volume":"161","author":[{"given":"Andrea M.","family":"Gross","sequence":"first","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia H.","family":"Reid","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cannon","sequence":"additional","affiliation":[{"name":"Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoyoung","family":"Choo-Wosoba","sequence":"additional","affiliation":[{"name":"Office of Collaborative Biostatistics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Office of Collaborative Biostatistics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Lobbous","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heersink School of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Wolters","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique C.","family":"Pichard","sequence":"additional","affiliation":[{"name":"Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland"},{"name":"Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia M.","family":"Tibery","sequence":"additional","affiliation":[{"name":"Leidos Biomedical Research, Inc, Frederick, Maryland"},{"name":"Clinical Research Directorate (CRD), Frederick National Laboratory for Cancer Research, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Derdak","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Korf","sequence":"additional","affiliation":[{"name":"Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"115","key":"dbr240028r1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","article-title":"Neurofibromatosis type 1 (NF1): diagnosis and management.","volume":"115","author":"Ferner","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"dbr240028r2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1212\/WNL.0000000000005792","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues.","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"dbr240028r3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Suppl 3","key":"dbr240028r4","doi-asserted-by":"publisher","first-page":"iii420","DOI":"10.1093\/neuonc\/noaa222.619","article-title":"NFB-17: MEK inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1\u2013associated plexiform neurofibromas: a report from PNOC and the NF Clinical Trials Consortium.","volume":"22","author":"Mueller","year":"2020","journal-title":"Neuro Oncol"},{"issue":"7","key":"dbr240028r5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas.","volume":"39","author":"Weiss","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"dbr240028r6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas.","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"dbr240028r7","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas.","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"dbr240028r8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-018-0772-z","article-title":"Cutaneous neurofibromas in neurofibromatosis type I: a quantitative natural history study.","volume":"13","author":"Cannon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"dbr240028r9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/cancers13030463","article-title":"Cutaneous findings in neurofibromatosis type 1.","volume":"13","author":"Ozarslan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7 Suppl 1","key":"dbr240028r10","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1212\/WNL.0000000000012427","article-title":"Measuring the effect of cutaneous neurofibromas on quality of life in neurofibromatosis type 1.","volume":"97","author":"Maguiness","year":"2021","journal-title":"Neurology"},{"issue":"7 Suppl 1","key":"dbr240028r11","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1212\/WNL.0000000000012425","article-title":"Perspective of adults with neurofibromatosis 1 and cutaneous neurofibromas: implications for clinical trials.","volume":"97","author":"Cannon","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"dbr240028r12","first-page":"i107","article-title":"Management of cutaneous neurofibroma: current therapy and future directions.","volume":"2","author":"Chamseddin","year":"2019","journal-title":"Neurooncol Adv"},{"issue":"1","key":"dbr240028r13","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1038\/s41467-018-07452-y","article-title":"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.","volume":"9","author":"Brosseau","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"dbr240028r14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2159-8290.CD-18-0156","article-title":"Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells.","volume":"9","author":"Radomska","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"dbr240028r15","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1212\/WNL.0000000000012428","article-title":"Validating techniques for measurement of cutaneous neurofibromas: recommendations for clinical trials.","volume":"97","author":"Thalheimer","year":"2021","journal-title":"Neurology"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2830418\/jamadermatology_gross_2025_br_240028_1747728388.11474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:00:39Z","timestamp":1747825239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2830418"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.6574","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}